Art. -Nr.: HY-134836

STM2457

113 Cited Publications

Kundenbewertung

Based on 113 publication(s) in Google Scholar

STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.55%
CAS. Nr.: 2499663-01-1
Formel: C₂₅H₂₈N₆O₂
Molecular Weight:444.53

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

STM2457 Chemical Structure

CAS. Nr.: 2499663-01-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (113)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML)^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
EOL1	IC₅₀	1.94 μM Compound: 3b; STM2457	Antiproliferative activity against human EOL1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human EOL1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
HL-60	IC₅₀	10.3 μM Compound: 3b; STM2457	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
Huh-7	GI₅₀	0.6 μM Compound: 8; STM2457	Growth inhibition of human Huh-7 cells Growth inhibition of human Huh-7 cells	[PMID: 38805939]
Kasumi 1	IC₅₀	0.7 μM Compound: 3b; STM2457	Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
MOLM-13	IC₅₀	1.04 μM Compound: 3b; STM2457	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
NCI-H1975	IC₅₀	65.8 μM Compound: STM2457	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 39291017]
NOMO-1	IC₅₀	0.6 μM Compound: 3b; STM2457	Antiproliferative activity against human NOMO-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human NOMO-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
OCI-AML2	IC₅₀	1.78 μM Compound: 3b; STM2457	Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
OCI-AML-3	IC₅₀	3.2 μM Compound: 3b; STM2457	Antiproliferative activity against human OCI-AML-3 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human OCI-AML-3 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]
PC-9	IC₅₀	69.15 μM Compound: STM2457	Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 39291017]
THP-1	IC₅₀	1.5 μM Compound: 3b; STM2457	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay	[PMID: 36692498]

In Vitro

STM2457 (Compound 72) inhibits MOLM13 cells proliferation with an IC₅₀ of 8.699 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2499663-01-1
Appearance Solid
Molecular Weight 444.53
Formel C₂₅H₂₈N₆O₂
Color White to yellow
SMILES

O=C(C(N=C1N2C=CC=C1)=CC2=O)NCC3=CN4C=C(CNCC5CCCCC5)C=CC4=N3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (113)

All WBRT-PCRIF

Sort by:

Journal Impact Factor

Cell

Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation. [Abstract]

2025 Feb 20;188(4):998-1018.e26. PMID: 39826545
Nat Biotechnol

Programmable protein expression using a genetically encoded m6A sensor. [Abstract]

2024 Sep;42(9):1417-1428. PMID: 38168988
Nat Biotechnol

Absolute quantification of single-base m6A methylation in the mammalian transcriptome using GLORI. [Abstract]

2023 Mar;41(3):355-366. PMID: 36302990
Gastroenterology

METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. [Abstract]

2022 Oct;163(4):891-907. PMID: 35700773
Cancer Commun (Lond)

Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m6A-dependent manner. [Abstract]

2025 Nov;45(11):1583-1610. PMID: 41103024
Cancer Commun (Lond)

m6 A-mediated regulation of PBX1-GCH1 axis promotes gastric cancer proliferation and metastasis by elevating tetrahydrobiopterin levels. [Abstract]

2022 Apr;42(4):327-344. PMID: 35261206

STM2457 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2022 Apr;42(4):327-344. [Abstract]

The protein levels of PBX1 and GCH1 decreased in AGS cells treated with STM2457 (10 μM; 0–48 h), while METTL3 levels showed no change (upper panel).
Nat Methods

Mild and ultrafast GLORI enables absolute quantification of m6A methylome from low-input samples. [Abstract]

2025 Jun;22(6):1226-1236. PMID: 40325216
Nat Genet

Crosstalk between RNA m6A and DNA methylation regulates transposable element chromatin activation and cell fate in human pluripotent stem cells. [Abstract]

2023 Aug;55(8):1324-1335. PMID: 37474847
Bioact Mater

Preventing postsurgical colorectal cancer relapse: A hemostatic hydrogel loaded with METTL3 inhibitor for CAR-NK cell therapy. [Abstract]

2024 Oct 22:44:236-255. PMID: 39497707
Cell Stem Cell

N6-methyladenosine on L1PA governs the trans-silencing of LTRs and restrains totipotency in naive human embryonic stem cells. [Abstract]

2025 Oct 29:S1934-5909(25)00371-6. PMID: 41167193
Autophagy

Chaperone-mediated autophagy reprograms heterogeneous subsets of activated macrophages in immune thrombocytopenia. [Abstract]

2026 Jun 26:1-17. PMID: 42329073
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Rewired m6A of promoter antisense RNAs in Alzheimer's disease regulates neuronal genes in 3D nucleome. [Abstract]

2025 Jun 6;16(1):5251. PMID: 40480976

STM2457 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jun 6;16(1):5251. [Abstract]

RT-qPCR data showed m6A methylation and MAPT-paRNA expression with and without STM2457 (10 μM; 24 h) treatment in induced pluripotent stem cell (iPSC)-derived human excitatory neurons (i3Neurons).
Nat Commun

DHX36 binding induces RNA structurome remodeling and regulates RNA abundance via m6A reader YTHDF1. [Abstract]

2024 Nov 15;15(1):9890. PMID: 39543097
Nat Commun

METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming during senescence. [Abstract]

2024 Jun 26;15(1):5410. PMID: 38926365

STM2457 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 26;15(1):5410. [Abstract]

Incubated RAS-induced senescent cells with antibodies targeting YTHDF3 and TIAR when treated with DMSO or METTL3 inhibitor (2.5 μM STM2457) for 48 h.
Nat Commun

Multigenerational paternal obesity enhances the susceptibility to male subfertility in offspring via Wt1 N6-methyladenosine modification. [Abstract]

2024 Feb 14;15(1):1353. PMID: 38355624

STM2457 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 14;15(1):1353. [Abstract]

STM2457 (50.0 mg/kg, once a week for 5 weeks) was administered. The protein level of testicular METTL3 was measured. n = 6 mice.
Redox Biol

Histone lactylation-regulated METTL3 promotes ferroptosis via m6A-modification on ACSL4 in sepsis-associated lung injury. [Abstract]

2024 Aug:74:103194. PMID: 38852200
Nucleic Acids Res

A nanopore-based HIV-1 reference epitranscriptome. [Abstract]

2026 Mar 19;54(6):gkag220. PMID: 41854072
Nucleic Acids Res

Increased PTCHD4 expression via m6A modification of PTCHD4 mRNA promotes senescent cell survival. [Abstract]

2024 Jul 8;52(12):7261-7278. PMID: 38721764

STM2457 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2024 Jul 8;52(12):7261-7278. [Abstract]

Presenescent WI-38 cells were incubated with the METTL3/METTL14 inhibitor STM2457 (2 μM) or with vehicle alone (DMSO) for 48 h.
J Exp Clin Cancer Res

METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. [Abstract]

2023 Mar 17;42(1):65. PMID: 36932427
Adv Sci (Weinh)

Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn's Disease by Interacting with OTUD4 and Activating the MYD88/NF-κB Pathway. [Abstract]

2025 Mar;12(11):e2409419. PMID: 39888301
Cell Rep Med

METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. [Abstract]

2023 Aug 15;4(8):101144. PMID: 37586322
Sci Adv

N6-methyladenosine modification-tuned lipid metabolism controls skin immune homeostasis via regulating neutrophil chemotaxis. [Abstract]

2024 Oct 4;10(40):eadp5332. PMID: 39356764
Cardiovasc Res

METTL3-catalyzed m6A methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. [Abstract]

2025 May 6;121(4):568-584. PMID: 39977233
Cell Death Dis

Downregulated Smad3 signaling impairs the maturation of MO-MDSC in colorectal cancer. [Abstract]

2025 Dec 8;16(1):880. PMID: 41360769
Cell Death Dis

ADAP-METTL3 modulates the inflammatory responses of macrophages via m6A modification of Spry1. [Abstract]

2025 Oct 7;16(1):708. PMID: 41057319
Environ Sci Technol

Ultrafine Particulate Matter Exacerbates the Risk of Delayed Neural Differentiation: Modulation Role of METTL3-Mediated m6A Modification. [Abstract]

2025 Feb 18;59(6):2974-2986. PMID: 39903687
Cell Death Dis

TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. [Abstract]

2024 Jun 17;15(6):422. PMID: 38886389
Blood Cancer Discov

METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL. [Abstract]

2023 May 1;4(3):228-245. PMID: 37067905
Cell Commun Signal

Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML. [Abstract]

2025 Mar 8;23(1):126. PMID: 40057764
Cell Commun Signal

METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma. [Abstract]

2023 May 25;21(1):121. PMID: 37231451
Mol Ther

Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification. [Abstract]

2025 Dec 3;33(12):6146-6159. PMID: 40914805
Phytomedicine

Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma. [Abstract]

2024 Dec:135:156002. PMID: 39326134
J Pharm Anal

Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer. [Abstract]

2023 Jun;13(6):625-639. PMID: 37440912
J Hazard Mater

Sperm Rhoa m6A modification mediates intergenerational transmission of paternally acquired hippocampal neuronal senescence and cognitive deficits after combined exposure to environmental cadmium and high-fat diet in mice. [Abstract]

2023 Sep 15:458:131891. PMID: 37354721
Cell Death Discov

METTL3-m6A-mediated TGF-β signaling promotes Fuchs endothelial corneal dystrophy via regulating corneal endothelial-to-mesenchymal transition. [Abstract]

2025 Mar 15;11(1):104. PMID: 40089501
J Orthop Translat

Magnesium ions facilitate osteogenic differentiation and intervertebral fusion via m6A methylation of RhoA mRNA. [Abstract]

2026 Feb 18:57:101056. PMID: 41757292
J Transl Med

HNRNPC modulates PKM alternative splicing via m6A methylation, upregulating PKM2 expression to promote aerobic glycolysis in papillary thyroid carcinoma and drive malignant progression. [Abstract]

2024 Oct 8;22(1):914. PMID: 39380010
Dev Cell

A microscopy-based CRISPR screening platform enables organellar functional genomics and illuminates ciliary biology. [Abstract]

2025 Nov 20:S1534-5807(25)00666-5. PMID: 41270742
Int J Biol Macromol

17-AAG promotes the degradation of HSP90 client METTL3 to suppress MYC RNA m6A modification and expression in colorectal cancer. [Abstract]

2025 Dec 3;337(Pt 1):149421. PMID: 41349747
EMBO J

The RNA m6A landscape during human oocyte-to-embryo transition. [Abstract]

2025 Jul;44(14):4150-4180. PMID: 40467862
Mol Med

Reciprocal METTL3-PAX5 regulation in maintaining B-cell identity and promoting B-cell hyperreactivity in SLE. [Abstract]

2025 Jun 12;31(1):236. PMID: 40506739
Free Radic Biol Med

Methyltransferase-like 3 mediates m6A modification of heme oxygenase 1 mRNA to induce ferroptosis of renal tubular epithelial cells in acute kidney injury. [Abstract]

2025 Mar 1:229:168-182. PMID: 39837470
Cell Rep

N(6)-methyladenosine modification of RNA is regulated by senataxin and E6 to control HPV replication. [Abstract]

2026 Jan 9;45(1):116828. PMID: 41518615
Cell Rep

Hyperacute response proteins synthesized on γ-tubulin-FTO-MARK4 translation microdomains regulate cancer's acute stress response. [Abstract]

2025 Jun 18;44(7):115871. PMID: 40540400
Cell Rep

m6A modification inhibits miRNAs' intracellular function, favoring their extracellular export for intercellular communication. [Abstract]

2024 Jun 14;43(6):114369. PMID: 38878288
Cell Rep

Alphaherpesvirus US3 protein-mediated inhibition of the m6A mRNA methyltransferase complex. [Abstract]

2022 Jul 19;40(3):111107. PMID: 35858564
Cell Prolif

Lin28a forms an RNA-binding complex with Igf2bp3 to regulate m6A-modified stress response genes in stress granules of muscle stem cells. [Abstract]

2024 Dec;57(12):e13707. PMID: 39021312
Virulence

HIV-1 Vpr activates microglia by upregulating m6A modification through ubiquitin-proteasome pathway-mediated degradation of the demethylase ALKBH5. [Abstract]

2026 Dec;17(1):2645908. PMID: 41824629
Discov Nano

The ginger-derived nanovesicles-coated albumin nanoparticles induce cell death and epigenetic regulation to treat colorectal cancer. [Abstract]

2026 May 28;21(1):223. PMID: 42207394
Ecotoxicol Environ Saf

N6-methyladenosine facilitates arsenic-induced neoplastic phenotypes of human bronchial epithelial cells by promoting miR-106b-5p maturation. [Abstract]

2024 Sep 15:283:116803. PMID: 39094460
Biochem Pharmacol

METTL3 regulates rifampicin-induced CYP3A4 expression by activating PXR translation and nuclear import and stabilizing CYP3A4 mRNA. [Abstract]

2025 Sep:239:117016. PMID: 40466953
Biochem Pharmacol

STM2457 decreases m6A methylation to reduce cisplatin-induced ototoxicity via MAPK signaling. [Abstract]

2025 May:235:116820. PMID: 39983847
Cancer Gene Ther

WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modification. [Abstract]

2026 Mar;33(3):277-288. PMID: 41981278
Life Sci

Inhibition of METTL3 alleviated LPS-induced alveolar epithelial cell apoptosis and acute lung injury via restoring neprilysin expression. [Abstract]

2023 Nov 15:333:122148. PMID: 37805166
Transl Res

ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression. [Abstract]

2023 Sep:259:62-71. PMID: 37121538
Cells

2026 Jan;15(3):294.
Cells

Epitranscriptomic Regulation of Platinum Resistance via the METTL3-ADAM23 Axis in Ovarian Cancer. [Abstract]

2026 Feb 4;15(3):294. PMID: 41677656
EMBO Rep

Arginine methylation-dependent METTL14-SMN interaction regulates RNA m6A homeostasis. [Abstract]

2025 Oct 6. PMID: 41053315
Mol Cancer Res

METTL3-mediated m6A modification regulates the polycomb repressive complex 1 (PRC1) components BMI1 and RNF2 in hepatocellular carcinoma cells. [Abstract]

2025 Mar 3;23(3):190-201. PMID: 39625677
Commun Biol

m6A modification regulates cell proliferation via reprogramming the balance between glycolysis and pentose phosphate pathway. [Abstract]

2025 Mar 26;8(1):496. PMID: 40140553
J Gastroenterol

Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2. [Abstract]

2026 Jun 11. PMID: 42274788
Biochim Biophys Acta Mol Basis Dis

METTL3 promotes human amniotic epithelial stem cells differentiation into insulin-producing cells by regulation of MaFA expression. [Abstract]

2025 Aug;1871(6):167904. PMID: 40374016
Biochim Biophys Acta Mol Basis Dis

TNF-α drives bladder cancer metastasis via METTL3-mediated m6A modification to promote CLASP2/IQGAP1-dependent cytoskeleton remodeling. [Abstract]

2025 Jun;1871(5):167811. PMID: 40118293
PLoS Pathog

Paramyxovirus matrix protein redirects METTL3 for dual regulation of viral replication and immune evasion. [Abstract]

2025 Dec 1;21(12):e1013755. PMID: 41325422
Exp Neurol

Drugs targeting synaptic RNA m6A methylation regulate synaptic transmission and plasticity in the rat hippocampus. [Abstract]

2026 Aug:402:115802. PMID: 42066972
Neuropharmacology

Emerging role of N6-methyladenosine (m6A) epitranscriptomic changes in adult anxiety after adolescent alcohol exposure. [Abstract]

2026 Mar 1:285:110777. PMID: 41276160
Med Oncol

Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment. [Abstract]

2026 Jan 20;43(2):122. PMID: 41557107
Cell Signal

Gambogic acid induces ferroptosis and suppresses colorectal cancer progression by modulating the m6A modification of p62. [Abstract]

2025 Nov:135:112024. PMID: 40721064
Cell Signal

tRNA methyltransferase DNMT2 promotes hepatocellular carcinoma progression and enhances Bortezomib resistance through inhibiting TNFSF10. [Abstract]

2025 Mar:127:111533. PMID: 39617358
Med Oncol

STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis. [Abstract]

2025 Feb 22;42(3):82. PMID: 39985567
J Inflamm Res

METTL3/IGF2BP2-Mediated m6A RNA Methylation Drives Alveolar Macrophage-Dependent Neutrophil Recruitment in Cigarette Smoke-Induced COPD. [Abstract]

2025 Oct 29:18:15033-15047. PMID: 41185691
iScience

N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes. [Abstract]

2023 Oct 13;26(10):108022. PMID: 37954137
Antiviral Res

Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m6A enzymatic activity. [Abstract]

2026 Apr:248:106376. PMID: 41722706
Biochim Biophys Acta Mol Cell Res

Heat shock protein 70 regulates m6A modification in response to heat shock in esophageal squamous cell carcinoma. [Abstract]

2025 Jul 24;1872(8):120027. PMID: 40714122
FASEB J

METTL3 and IGF2BP2 coordinately regulate FOSL1 mRNA via m6A modification, suppressing trophoblast invasion and contributing to fetal growth restriction. [Abstract]

2024 Nov 30;38(22):e70154. PMID: 39565355
Biology (Basel)

N6-Methyladenosine Directly Regulates CD40L Expression in CD4+ T Lymphocytes. [Abstract]

2023 Jul 14;12(7):1004. PMID: 37508433
J Virol

METTL3 regulates PRRSV replication by suppressing interferon beta through autophagy-mediated IKKε degradation. [Abstract]

2025 Jul 22;99(7):e0009825. PMID: 40548751
J Virol

The loss of hepatitis B virus receptor NTCP/SLC10A1 in human liver cancer cells is due to epigenetic silencing. [Abstract]

2024 Oct 22;98(10):e0118724. PMID: 39297647
J Biol Chem

Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion. [Abstract]

2024 May;300(5):107226. PMID: 38537697
J Endocrinol Invest

METTL3 overexpression and ATF6 silencing-induced Inhibition in HAS2 expression relieves PDGF-BB stimulation-induced HA production and the proliferation of human orbital fibroblasts in graves' ophthalmopathy. [Abstract]

2025 Jul 9. PMID: 40632442
BMC Genomics

Genome-wide analysis of lncRNA m6A methylation in the mouse cortex after repetitive mild traumatic brain injury. [Abstract]

2025 May 20;26(1):509. PMID: 40394496
Ren Fail

DKK3 promotes renal fibrosis by increasing MFF-mediated mitochondrial dysfunction in Wnt/β-catenin pathway-dependent manner. [Abstract]

2024 Dec;46(1):2343817. PMID: 38682264
Pathol Res Pract

METTL3 promotes ovarian cancer progression through YTHDF2-dependent degradation of GATA4. [Abstract]

2025 Sep 9:275:156224. PMID: 40945198
Genomics

m6A-RNA epitranscriptomes regulate splicing and neuronal development in the Pacific oyster Crassostrea gigas. [Abstract]

2025 Oct 13;117(6):111142. PMID: 41093079
Reproduction

METTL3-mediated m6A modification promotes ferroptosis in adenomyosis through GPX4 in a YTHDF1-dependent manner. [Abstract]

2025 Sep 19;170(4):e250251. PMID: 40911580
J Leukoc Biol

N6-Methyladenosine Promotes TNF mRNA Degradation In CD4+ T Lymphocytes. [Abstract]

2024 Oct 1;116(4):807-815. PMID: 38657004
J Cancer

METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation. [Abstract]

2024 Jul 16;15(15):4853-4865. PMID: 39132158
Mol Biol Rep

YTHDF proteins differentially regulate a subset of m6A-modified transcripts to restrain endothelial inflammation during homeostasis. [Abstract]

2026 Mar 18;53(1):510. PMID: 41848956
PLoS One

The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification. [Abstract]

2026 Mar 24;21(3):e0345744. PMID: 41875089
Biochemistry

Enzymatic Characterization of In Vitro Activity of RNA Methyltransferase PCIF1 on DNA. [Abstract]

2022 May 23;61(11):1005-1013. PMID: 35605980
Mol Reprod Dev

METTL3-Mediated m6A Modification Promotes the Stability of PLCζ mRNA in Sperm. [Abstract]

2026 May;93(5):e70106. PMID: 42112538
Sci Prog

Embryonic stem cell-derived small extracellular vesicles alleviate lead-induced cochlear spiral ganglion neurons injury by activating PI3 K/AKT signaling pathway. [Abstract]

2025 Jul-Sep;108(3):368504251358007. PMID: 40630004
Res Sq

2026 Apr 27.
bioRxiv

2026 Apr 14.
bioRxiv

2026 Mar 26.
bioRxiv

Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4+ T cells. [Abstract]

2026 Mar 18:2026.03.18.712554. PMID: 41890003
bioRxiv

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]

2026 Feb 18:2026.02.16.706212. PMID: 41757027
Res Sq

Inhibition of N6-Methyladenosine Accumulation by Targeting METTL3 Mitigates Tau Pathology and Cognitive Decline in Alzheimer's Disease. [Abstract]

2025 Dec 19:rs.3.rs-8379573. PMID: 41510223
SSRN

2025 Oct 24.
bioRxiv

2025 Sep 12.
bioRxiv

2025 Sep 3.
bioRxiv

2025 July 17.
Oncotarget

METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis. [Abstract]

2025 May 8:16:291-309. PMID: 40338154
bioRxiv

2025 April 08.
bioRxiv

2025 April 29.
bioRxiv

Rewired m6A methylation of promoter antisense RNAs in Alzheimer's disease regulates global gene transcription in the 3D nucleome. [Abstract]

2025 Mar 24:2025.03.22.644756. PMID: 40196645
bioRxiv

An HIV-1 Reference Epitranscriptome. [Abstract]

2025 Jan 31:2025.01.30.635805. PMID: 39975020
Res Sq

2024 Jul 08.
bioRxiv

2024 June 25.
Patent

US20240207446A1.
Research Square Preprint

2024 May 3.
Research Square Print

September 9th, 2022.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (224.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2496 mL

11.2478 mL

22.4957 mL

5 mM

0.4499 mL

2.2496 mL

4.4991 mL

10 mM

0.2250 mL

1.1248 mL

2.2496 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 3.33 mg/mL (7.49 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 20% HP-β-CD in Saline

Solubility: 5 mg/mL (11.25 mM); Clear solution; Need ultrasonic

Protocol 3

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water

Solubility: 5 mg/mL (11.25 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wesley Peter Blackaby, et al. Mettl3 inhibitory compounds. WO2020201773A1.

[2]. Eliza Yankova, et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021 Apr 26. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2496 mL	11.2478 mL	22.4957 mL	56.2392 mL
	5 mM	0.4499 mL	2.2496 mL	4.4991 mL	11.2478 mL
	10 mM	0.2250 mL	1.1248 mL	2.2496 mL	5.6239 mL
	15 mM	0.1500 mL	0.7499 mL	1.4997 mL	3.7493 mL
	20 mM	0.1125 mL	0.5624 mL	1.1248 mL	2.8120 mL
	25 mM	0.0900 mL	0.4499 mL	0.8998 mL	2.2496 mL
	30 mM	0.0750 mL	0.3749 mL	0.7499 mL	1.8746 mL
	40 mM	0.0562 mL	0.2812 mL	0.5624 mL	1.4060 mL
	50 mM	0.0450 mL	0.2250 mL	0.4499 mL	1.1248 mL
	60 mM	0.0375 mL	0.1875 mL	0.3749 mL	0.9373 mL
	80 mM	0.0281 mL	0.1406 mL	0.2812 mL	0.7030 mL
	100 mM	0.0225 mL	0.1125 mL	0.2250 mL	0.5624 mL

Keywords

STM2457

113 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

STM2457

Apoptosis Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Chemical Probe Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) STM2457

Biologische Aktivität

Chemical Information

Publications (113)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

STM2457

Apoptosis Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Chemical Probe Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) STM2457

Biologische Aktivität

Chemical Information

Publications (113)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

STM2457 Related Classifications

HY-134836 Related Classifications